Original Article
IJMDC. 2021; 5(2):
Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.
Authors: Hussein G Elsayed, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, Ahmed Zeineldeen.
ABSTRACT
Background: Tyrosine kinase inhibitors revolutionized the treatment of chronic myeloid leukemia. The present study aimed to review the efficacy and tolerance of Imatinib in a group of patients who are treated outside the clinical trial. Methodology: CML patients presenting to King Abdulla Medical (KAMC), Mecca, Saudi Arabia, during the period between June 2010 and December 2019 were included in this study. All started Imatinib as the first line. Evaluation of response was done according to ELN 2020 recommendation. Results: 141 patients were included in this study with a male to female ratio of 1.1 and a median age of 42. The majority of patients were considered to be at low risk (70.2%) as by EUTOS risk score. For the whole group, the median follow up was 47.7 months. At 36 m, the OS was 94.8%, which continued as there was no death afterward. Mean event-free survival was 65 m (95% CI 55.6-72.5) with a median of 56.5m. It was significantly longer in those with a low-risk score (p = 0.0001), patients with favorable molecular responses at 3,6,12 m, and compliant patients. Favorable molecular responses were obtained in 67%,53%,51% at 3,6,12 months respectively. Factors that affected molecular responses were higher Hemoglobin, higher platelets, lower blasts, basophils, low-risk score, and better compliance. Conclusion: In a real-life setting, the efficacy of Imatinib in CML patients was found high coupled with a safe toxicity profile.
Keywords:
CML, Imatinib, Saudi Arabia, real world.
Authors
Hussein G Elsayed
Hematology Department, King Abdullah Medical City, Makkah, Kingdom of Saudi Arabia.
PubMed articlesGoogle scholar articles
Moayyad Jalal
Umm Al-Qura University, Mekkah, Kingdom of Sauid Arabia.
PubMed articlesGoogle scholar articles
Anas Almarrakshi
Umm Al-Qura University, Mekkah, Kingdom of Sauid Arabia.
PubMed articlesGoogle scholar articles
Ahlam Almasaari
Hematology Department, King Abdullah Medical City, Makkah, Kingdom of Saudi Arabia.
PubMed articlesGoogle scholar articles
Amal Alabulwahab
Hematology Department, King Abdullah Medical City, Makkah, Kingdom of Saudi Arabia.
PubMed articlesGoogle scholar articles
Fatimah Alhawsawi
Umm Al-Qura University, Mekkah, Kingdom of Sauid Arabia.
PubMed articlesGoogle scholar articles
Amjad Alharbi
Umm Al-Qura University, Mekkah, Kingdom of Sauid Arabia.
PubMed articlesGoogle scholar articles
Asmaa Almaddani
Cancer Registry, King Abdullah Medical City, Mekkah, Kingdom of Saudi Arabia.
PubMed articlesGoogle scholar articles
Ahmed Zeineldeen
Medical Oncology Department, King Abdullah Medical City, Mekkah, Kingdom of Saudi Arabia.
PubMed articlesGoogle scholar articles
Correspondence to:
. Hematology Department, King Abdullah Medical City, Makkah, Kingdom of Saudi Arabia.; husseingaballa@yahoo.com
Publication history
Received 20 Jan 2021
Accepted 21 Jan 2021
Published online 21 Jan 2021
How to cite this article?
Export to EndNote Export to refManPubmed Style
Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC. Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
Web Style
Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. https://www.ijmdc.com/?mno=47229 [Access: August 18, 2022]. doi:10.24911/IJMDC.51-1611143630
AMA (American Medical Association) Style
Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC. Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
Vancouver/ICMJE Style
Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC, [cited August 18, 2022]; Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
Harvard Style
Elsayed, H. G., Jalal, . M., Almarrakshi, . A., Almasaari, . A., Alabulwahab, . A., Alhawsawi, . F., Alharbi, . A., Almaddani, . A. & Zeineldeen, . A. (2021) Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC, Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
Turabian Style
Elsayed, Hussein G, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, and Ahmed Zeineldeen. 2021. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. International Journal of Medicine in Developing Countries, Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
Chicago Style
Elsayed, Hussein G, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, and Ahmed Zeineldeen. "Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.." International Journal of Medicine in Developing Countries Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
MLA (The Modern Language Association) Style
Elsayed, Hussein G, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, and Ahmed Zeineldeen. "Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.." International Journal of Medicine in Developing Countries Online First: 21 Jan, 2021. Web. 18 Aug 2022 doi:10.24911/IJMDC.51-1611143630
APA (American Psychological Association) Style
Elsayed, H. G., Jalal, . M., Almarrakshi, . A., Almasaari, . A., Alabulwahab, . A., Alhawsawi, . F., Alharbi, . A., Almaddani, . A. & Zeineldeen, . A. (2021) Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. International Journal of Medicine in Developing Countries, Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630
Article Statistics
Request permissions
If you wish to reuse any part or all of this article please contact the copyright holder, contact@ijmdc.com.
Copyright ©2022 Discover STM Publishing. All Rights Reserved.